Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines

10 May 2021

Abstract excerpt

All available vaccines for coronavirus disease 2019 (COVID-19) express or deliver the full-length SARS-CoV-2 spike (S) protein. We show that this antigen is not optimal, consistent with observations that the vast majority of the neutralizing response to the virus is focused on the S-protein receptor-binding domain (RBD). However, this RBD is not expressed well as an independent domain, especially when expressed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33975938
DOI: 10.1128/mbio.00930-21

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 VaccinesPMID 33975938Read ↗

Design of SARS-CoV-2 RBD Immunogens to Focus Immune Responses Towards Conserved Coronavirus EpitopesSemantic proximity Read ↗

Antibodies and Vaccines Target RBD of SARS-CoV-2Semantic proximity Read ↗

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1Semantic proximity Read ↗

Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse ModelSemantic proximity Read ↗

Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive VaccinesSemantic proximity Read ↗

Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronavirusesSemantic proximity Read ↗

Designed SARS‐CoV‐2 receptor binding domain variants form stable monomersSemantic proximity Read ↗

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoVSemantic proximity Read ↗

Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in miceSemantic proximity Read ↗

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic AntibodiesSemantic proximity Read ↗

A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered Pichia pastoris Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody ResponsesSemantic proximity Read ↗

SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.